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Abstract
Background: Ibuprofen and paracetamol differ in their mode of action and related therapeutic effects, suggesting that 
combined administration may offer improved analgesia. Reported here are the results of two studies on the 
pharmacokinetic properties of a novel ibuprofen (200 mg) and paracetamol (500 mg) fixed-dose combination tablet.
Methods: Both studies were open-label, randomised studies in healthy volunteers: Study 1 was a four-way crossover, 
single-dose study; Study 2 was a two-way cross-over, repeat-dose study.
Results: Pharmacokinetic parameters for ibuprofen and paracetamol were similar for the combination and 
monotherapy tablets (values falling within the 80% to 125% acceptable bioequivalence range) except for the rate of 
absorption of paracetamol from the combination (tmax), which was significantly faster compared with monotherapy 
(median difference 10 minutes; p < 0.05). Mean plasma concentrations of both drugs were higher, earlier, following 
administration of the combination tablet compared with monotherapy. Mean plasma levels at 10 and 20 minutes were 
6.64 μg.mL-1 and 16.81 μg.mL-1, respectively, for ibuprofen from the combination, compared with 0.58 μg.mL-1 and 9.00 
μg.mL-1, respectively, for monotherapy. For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 μg.mL-1 
and 14.54 μg.mL-1, respectively, for the combination compared with 0.33 μg.mL-1 and 9.19 μg.mL-1, respectively, for 
monotherapy. The rate of absorption of both ibuprofen and paracetamol was significantly delayed when the 
combination tablet was administered in the fed versus fasted state; median delay was 25 minutes for ibuprofen (p > 
0.05) and 55 minutes for paracetamol (p < 0.001). The pharmacokinetic parameters were comparable irrespective of 
whether the combination tablet was given twice or three times daily; systemic exposure was, however, approximately 
1.4 times greater for both drugs when given three times daily.
Conclusions: Administration of ibuprofen and paracetamol in a fixed-dose combination tablet does not significantly 
alter the pharmacokinetic profiles of either drug, except for enhancing the rate of paracetamol absorption, offering 
potential therapeutic benefits in relation to the onset of analgesia. Concentrations of both drugs reached previously 
reported therapeutic levels when the combination tablet was administrated in the fed or fasted state. Three times daily 
dosing may offer enhanced therapeutic effect for longer than twice daily dosing.
Background
Ibuprofen and paracetamol are the most commonly used
non-prescription analgesics. These two compounds differ
in their mode of action. Ibuprofen is a non-steroidal anti-
inflammatory drug (NSAID) that inhibits cyclooxygenase
enzymes (COX-1 and COX-2) and subsequent synthesis
of prostaglandins and related compounds at peripheral
sites within injured tissue [1]. The mode of action of par-
acetamol is not completely understood, but appears to be
related to the inhibition of a sub-class of cyclooxygenase
enzyme isoforms in the central nervous system [2].
Both ibuprofen and paracetamol are rapidly absorbed
after oral administration, with peak serum concentra-
tions occurring within one to two hours for ibuprofen
and between 30 minutes and two hours for paracetamol.
Both drugs have plasma half lives of approximately two
hours, although in the case of paracetamol this can vary
between one and four hours [3]. Ibuprofen is extensively
bound to plasma proteins (99%) and extensively metabo-
lised in the liver to two major inactive metabolites that
are rapidly and completely excreted by the kidneys. In
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contrast, paracetamol has low plasma binding (20%) and
although also extensively metabolised in the liver to two
groups of major metabolites, the sulphate conjugates of
these metabolites can accumulate in the event of over-
dose, due to enzyme saturation. Paracetamol also differs
from ibuprofen in that it has no anti-inflammatory
actions. Furthermore, paracetamol is observed to provide
less effective analgesia than NSAIDs in some indications
such as dental pain and sore throat [4,5].
Taken together these differing modes of action and
related therapeutic effects suggest that ibuprofen and
paracetamol may complement each other and improved
analgesia may be obtained using a combination, com-
pared with individual administration. A fixed-dose com-
bination tablet offers the advantages of patient
compliance and convenience, although it potentially lim-
its the scope for dosage adjustment. A small study on the
pharmacokinetic properties of ibuprofen and paraceta-
mol, when taken concurrently, found no significant
change in kinetic parameters of the two drugs [6]. Here
we report the findings of two studies on the pharmacoki-
netic properties of a novel ibuprofen (200 mg) and parac-
etamol (500 mg) fixed-dose combination tablet. These
studies were conducted to investigate the bioavailability,
and effect of food on bioavailability, of ibuprofen and par-
acetamol from this novel single tablet combination and to
determine that there was no pharmacokinetic drug-drug
interaction when these two drugs are combined in a sin-
gle tablet.
Methods
Study design and objectives
These studies were designed to determine the pharma-
cokinetic properties of a novel fixed-dose combination
tablet of ibuprofen (200 mg) and paracetamol (500 mg).
The primary objective of Study 1 was to show that the
pharmacokinetic profiles of ibuprofen and paracetamol
do not change significantly when administered as a fixed-
dose combination tablet compared with monotherapy.
The primary objective of Study 2 was to investigate the
pharmacokinetic profiles of ibuprofen and paracetamol
following twice or three times daily dosing with a fixed-
dose combination tablet. The secondary objectives were
to investigate the effects of food intake on the single dose
pharmacokinetic profiles of the fixed-dose combination
tablet (Study 1) and to assess its safety profile in healthy
volunteers (Study 1 and 2). The studies were designed in
accordance with the Committee for Proprietary Medici-
nal Products on the investigation of bioavailability and
bioequivalence guidelines on fixed combination products
[7,8] and US Food and Drug Administration guidance for
industry on bioavailability and bioequivalence of oral
drugs and food effect [9,10].
Study 1 was an open-label, four-way crossover, ran-
domised, single-dose, single centre, pharmacokinetic
study and Study 2 was an open-label, two-way, cross-over,
randomised, repeat-dose, single centre, pharmacokinetic
study. Both studies were in healthy volunteers and were
approved by the South East Wales Research Ethics Com-
mittee and conducted in accordance with the Declaration
of Helsinki, International Conference on Harmonisation
(ICH), Good Clinical Practice (GCP) and applicable regu-
latory requirements. All participants provided written
informed consent.
Participant selection
The within-subject coefficient of variation for paraceta-
mol maximum plasma concentration (Cmax) was previ-
ously estimated to be approximately 25% (unpublished
results; Simbec Internal Study Report). Using the method
of Diletti [11] a sample size of 24 was calculated to be suf-
ficient to detect a 20% difference between the test and
reference formulation, with a power of 80% and an alpha
of 5% based on a test versus reference ratio of 1.0. In both
studies 26 subjects were enrolled to allow for dropouts.
Subjects were recruited from Simbec Research Ltd
(Merthyr Tydfil, Wales, UK) volunteer database and were
required to be healthy, between 18 and 75 years of age
and have a body mass index (BMI) of 20-27 kg/m2. Inter-
ested subjects were screened for suitability; screening
included recording of demographic data and vital signs,
physical examination, medical history, current medical
status, prior medication (within 14 days of screening) and
concomitant medication. Individuals were not considered
suitable if they had a significant history of disease, metab-
olism disorder or allergy relating to ibuprofen, aspirin,
other NSAID or paracetamol, or if they had a history of
peptic or duodenal ulcers, gastrointestinal bleeding, fre-
quent dyspepsia or migraine. Other exclusion criteria
included a history of drug or alcohol abuse, positive HIV
status or known risk factors for AIDS, participation in
another trial within 12 weeks of screening, being a cur-
rent smoker (or having smoked within the previous six
months), taking a prescribed drug within 14 days of
enrolment or an over the counter drug within seven days
(excluding the contraceptive pill or hormone replacement
therapy).
A blood sample was taken for haematology, biochemis-
try and virology screening, together with serum preg-
nancy test for female subjects. In addition, a urine sample
was taken for urinalysis and alcohol and drug testing.
Treatment and study procedures
In Study 1, subjects were randomised to receive two ibu-
profen 200 mg tablets following an overnight fast, two
paracetamol 500 mg tablets following an overnight fast or
two fixed-dose combination tablets (ibuprofen 200 mgTanner et al. BMC Clinical Pharmacology 2010, 10:10
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plus paracetamol 500 mg) following an overnight fast, or
a standard meal. Treatment was repeated on four occa-
sions, with a washout period of between three and seven
days between treatments. Blood samples were taken for
pharmacokinetic sampling prior to dosing and post dose
at 5, 10, 20, 30 and 40 minutes and 1, 1.25, 1.5, 2, 3, 6, 9
and 12 hours.
In Study 2, subjects were randomised to receive either
twice daily (12 hourly) or three times daily (8 hourly) dos-
ing of two fixed-dose combination tablets (ibuprofen 200
mg plus paracetamol 500 mg), for three days on two sepa-
rate occasions. Subjects randomised to receive twice daily
dosing received a total of 800 mg of ibuprofen and 2000
m g  o f  p a r a c e t a m o l  p e r  d a y ,  a n d  s u b j e c t s  o n  t h e  t h r e e
times daily dosing schedule received a total of 1200 mg of
ibuprofen and 3000 mg of paracetamol per day. A wash-
out period of between three and seven days was allowed
between treatments. Subjects attended the treatment
centre the night before treatment (Day 1) and fasted over-
night for approximately 10 hours. They then received
their first dose at about 07.00 on Day 2 and, in the case of
twice daily dosing, their second dose at about 19.00, two
hours after dinner. For three times daily dosing, subjects
received their second dose at about 15.00, three hours
after lunch, and their third dose at about 23.00, two hours
after receiving an evening snack. On Days 2 and 4, blood
samples were taken for pharmacokinetic sampling prior
to dosing and post Dose 1 at 10, 20, 40 and 60 minutes
and 1.5, 2, 3, 6, 8 and 12 hours. Further samples were
taken prior to administration of Dose 3 on Day 2, prior to
administration of all three doses on Day 3 and at 16, 17,
18, 20 and 24 hours post Dose 1 on Day 4.
Laboratory procedures
All haematology, biochemistry and urinary analyses were
conducted using standard methodologies, within a single
laboratory. Plasma concentrations of ibuprofen and par-
acetamol were analysed using liquid chromatography-
mass spectrometry procedures, which were fully vali-
dated and developed from methods previously used by
Simbec Research Ltd (Simbec Data on File).
Paracetamol plasma concentrations were analysed
using a liquid:liquid extraction (3:2; diethylether:dichlo-
romethane mixture) followed by LC-MS-MS analysis
using a Zorbax SB-C18 column (Agilent Technologies,
Santa Clara, USA). The mobile phase consisted of 500 mL
methanol, 500 mL water and 5 mL formic acid with an
isocratic flow rate of 0.6 mL.min-1 (based on a previously
published method) [12].
Ibuprofen plasma concentrations were analysed using a
protein precipitation extraction (acetonitrile containing
internal standard flurbiprofen) and by LC-MS analysis
using a Thermo Electron HyPurity® C18 column (Thermo
Electron Corporation, Massachusetts, USA). The mobile
phase consisted of 49.95% (v:v) of 10 mM ammonium
acetate, 49.95% (v:v) of acetonitrile and 0.10% (v:v) of gla-
cial acetic acid with an isocratic flow rate of 0.21 mL.min-1.
Pharmacokinetic and safety endpoints
Pharmacokinetic parameters for ibuprofen and paraceta-
mol were calculated using WinNonLin Pro® version 5.0.1
(Pharsight Corporation, California, USA). In Study 1, the
pharmacokinetic parameters assessed were maximum
concentration (Cmax); time to first occurrence of the max-
imum plasma concentration (tmax); plasma concentration
half life (t1/2); elimination rate constant (Kel), calculated
from the slope of the terminal portion of the plasma pro-
file calculated by least-square regression of log.(concen-
tration) against time; area under the plasma
concentration-time curve to the last measurable plasma
concentration (AUC0-t), calculated by the linear trapezoi-
dal rule; and area under the curve calculated by linear
trapezoidal rule to the last measurable plasma concentra-
tion (Cp) ,  w i t h  a d d i t i o n a l  a r e a  c a l c u l a t e d  f r o m  C p/Kel
(AUC0-inf).
On Day 2 in Study 2, the pharmacokinetic parameters
assessed after Dose 1 were Cmax, tmax, AUC0-t and AUC0-
inf. On Day 4, these same parameters were re-evaluated in
addition to the minimum plasma concentration (Cmin),
the average plasma concentration (Cav), fluctuation
([Cmax-Cmin]/Cav) and the area under the curve calculated
by linear trapezoidal rule during a dosage interval in
steady state (AUCtau).
Safety was assessed in terms of the overall proportion
o f  s u b j e c t s  w i t h  a d v e r s e  e v e n t s  ( A E s ) .  S u b j e c t s  w e r e
asked 'Are you experiencing any symptoms or com-
plaints?' at their baseline visit and 'Have you had any
symptoms or complaints since you were last asked?' at
each treatment visit and specified time points during the
study. AEs in response to this questioning or spontane-
ously reported by subjects were coded using the Med-
DRA version 9.0 dictionary. All AEs were followed-up
and recorded by severity (mild, moderate or severe) and
relationship to study medication (definite, probable, pos-
sible, unlikely, or none).
Statistical methods
SAS for Windows 9.1.3 software (SAS Institute Inc., Cary,
USA) was used for all statistical calculations. For the cal-
culation of AUCs, the actual rather than nominal sam-
pling time was used in calculations and no imputation
methods were used for missing data points.
For Study 1 results, following logarithmic transforma-
tion, Cmax, AUC0-t and AUC0-inf values were subjected to
an analysis of variance (ANOVA), including terms for
sequence, subject nested within sequence, period and
treatment. Contrasts between each pair of treatmentsTanner et al. BMC Clinical Pharmacology 2010, 10:10
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(least square [LS] means) were presented together with
90% confidence intervals (CIs) for the difference between
treatments constructed using the residual mean square
error obtained from the ANOVA. The point and interval
estimates were then back transformed to give estimates of
the LS geometric mean ratios and their corresponding
90% CI. tmax was analysed between each pair of treat-
ments using the Wilcoxon matched pairs test. In addition,
95% non-parametric CIs were constructed for the median
differences in the tmax values based on the Hodges-Leh-
mann estimates.
In Study 2, logarithmically transformed trough values
on Days 2, 3 and 4 were used to determine if a steady state
had been reached for both treatments. The point esti-
mates were then back-transformed to give estimates of
the ratios of the geometric means and the corresponding
95% CI and paired t-tests were also used for each treat-
ment. Following logarithmic transformation, Cmax  and
AUC0-t  values on Day 4 were subjected to ANOVA
including terms for sequence, subject nested within
sequence and period of treatment. Point estimates (using
LS) and 90% CIs of the differences between treatments
were constructed using the residual mean square error
obtained from the ANOVA. The point and interval esti-
mates were then back-transformed to give estimates of
the LS geometric mean ratios and their corresponding
90% CIs. In addition, logarithmic AUCtau on Day 4 and
AUC0-inf on Day 2 were subject to an ANOVA (by treat-
ment), including terms for sequence, subject nested
within sequence and day. For comparison, point esti-
mates and 90% CIs for the difference between Day 4 and
Day 2 were constructed for each treatment using the
residual mean square error obtained from the ANOVA.
The point and interval estimates were then back-trans-
formed to give estimates of the LS geometric mean ratios
and their corresponding 90% CIs.
In both studies the Fisher Exact Test was used to com-
pare the incidence of AEs, in addition to those described
as definitely, probably or possibly related to study treat-
ment.
Results
Patient enrolment
Forty five subjects were screened for Study 1, of which 27
were enrolled and 25 subjects completed the study. In
Study 2, of 33 subjects screened 26 were enrolled on the
study. The average age of participants was similar in both
studies; 31 years (range 18-57 years) in Study 1 and 33
years (range 20-59 years) in Study 2. The mean BMI and
sex distribution were also similar in both studies; mean
BMI of 24.5 and 24.4 in Study 1 and 2, respectively, and
16 and 17 subjects were male in Study 1 and 2, respec-
tively. Participants in both studies were current non-
smokers and the majority consumed between one and 20
units of alcohol per week.
Plasma concentration following combination therapy 
versus monotherapy
The dissolution of the fixed-dose combination tablet has
previously been observed to be rapid, with approximately
80% of ibuprofen and paracetamol dissolved within 10
minutes (data not shown). The observed rate and extent
of absorption of both ibuprofen and paracetamol from
the fixed-dose combination tablet was considered to be
bioequivalent to that of monotherapy; however, the rate
of absorption of paracetamol was significantly faster for
the combination tablet compared with paracetamol
monotherapy. The median tmax for ibuprofen was 75 min-
utes for both the combination tablet and monotherapy
(Table 1). In contrast, the median tmax for paracetamol
was 30 minutes for the combination tablet and 40 min-
utes for monotherapy, giving a statistically significant
median difference in tmax of 10 minutes (p < 0.05) in
favour of the combination tablet.
Mean plasma concentrations of both ibuprofen and
paracetamol were higher, earlier, following administra-
tion of the fixed-dose combination tablet compared with
administration of the corresponding monotherapy (Table
1, Figure 1 and Figure 2). In subjects receiving the combi-
nation tablet the mean ibuprofen plasma levels were 6.64
μg.mL-1 and 16.81 μg.mL-1 at 10 and 20 minutes, respec-
tively, compared with levels of 0.58 μg.mL-1  and 9.00
μg.mL-1, respectively, in subjects receiving ibuprofen
monotherapy. Similarly, mean plasma concentrations of
paracetamol at 10 and 20 minutes in subjects receiving
the combination tablet were 5.43 μg.mL-1  and 14.54
μg.mL-1, respectively, compared with values of 0.33
μg.mL-1 and 9.19 μg.mL-1, respectively, for paracetamol
monotherapy.
The pharmacokinetic parameters Cmax, AUC0-t  and
AUC0-inf  for ibuprofen and paracetamol were similar
between the fixed-dose combination and monotherapy
tablets (Table 1). The back-transformed 90% CIs for the
Cmax, AUC0-t and AUC0-inf ratios fell within the 80% to
125% acceptable bioequivalence range.
Fed versus fasted pharmacokinetic profiles
The absorption of both ibuprofen and paracetamol was
significantly delayed when the fixed-dose combination
tablet was administrated following a standard meal com-
pared with when it was administered to participants in
the fasted state (Table 2, Figure 3). Median delay in rate of
absorption was 25 minutes for ibuprofen (p > 0.05) and
55 minutes for paracetamol (p < 0.001). This delay was
associated with a reduced Cmax for both ibuprofen and
paracetamol when the combination tablet was adminis-Tanner et al. BMC Clinical Pharmacology 2010, 10:10
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tered in the fed state; the back-transformed 90% CIs for
the Cmax for ibuprofen and paracetamol were outside of
the bioequivalence acceptance range of 80% to 125%. In
addition, the ibuprofen t1/2 was prolonged when the com-
bination tablet was given in the fed versus fasted state,
although the paracetamol t1/2 did not differ.
In the fed state, the extent of absorption, as indicated by
AUC0-t, of both ibuprofen and paracetamol from the
fixed-dose combination tablet was slightly less compared
with the fasted state (Table 2), although the back-trans-
formed 90% CIs for the AUC0-t, along with AUC0-inf,
ratios fell within the bioequivalence acceptance range.
Pharmacokinetic profiles of twice versus three times daily 
dosing
In Study 2 the pharmacokinetic parameters for paraceta-
mol, from the fixed-dose combination tablet, were similar
f o l l o w i n g  a d m i n i s t r a t i o n  o f  t h e  f i r s t  d o s e  o f  b o t h  t h e
twice and three times daily dosing regime. However, for
ibuprofen a slightly shorter tmax and higher Cmax values
were observed for the three compared with twice times
daily dosing schedule (Table 3).
Following three days of treatment (on Day 4) the mean
plasma exposures after multiple dosing (AUCtau) (Table
4) were comparable to those observed after a single dose
(AUC0-inf) (Table 1). The LS geometric mean ratios for
ibuprofen were 90.28 and 86.50 following twice and three
times daily dosing, respectively, and 105.60 and 97.79,
respectively, for paracetamol; the 90% CI fell within 80 to
110%. Furthermore, irrespective of whether the combina-
tion tablet was given twice or three times daily, the Cmax
values observed for ibuprofen and paracetamol were
comparable, with LS geometric mean ratios of 100.58 and
98.51, respectively; and the 90% CI fell within the
bioequivalence acceptance range of 80 to 125%. The sys-
temic exposure, indicated by AUC0-t, was approximately
1.4 times greater for both ibuprofen and paracetamol
when the fixed-dose combination tablet was given three
times rather than twice a day, reflecting the additional
treatment dose.
Table 1: Mean derived pharmacokinetic profiles of ibuprofen and paracetamol after administration of the fixed-dose 
combination tablet compared with monotherapy (Study 1)
Ibuprofen
 (combination)
Ibuprofen 
(monotherapy)
Paracetamol 
(combination)
Paracetamol 
(monotherapy)
n 25 25 25 25
tmax, hrs (median difference [minutes], 
95% CI)
1.25a
(7.5, -15.0-37.5)
1.25a 0.50a
(-15.0, -30.0-0.0)
0.67a
t1/2, hrs 1.95 1.97 2.83 2.66
Cmax, μg.mL-1 32.04 30.89 18.48 17.49
LS geometric means (ratio test/reference 
[%], 90% CI)
31.46 (104.29, 95.90-113.41) 30.16 17.58 (104.14, 91.32-118.76) 16.88
AUC0-t, μg.mL-1.hr 118.32 111.59 51.69 49.47
LS geometric means (ratio test/reference 
[%], 90% CI)
116.51 (107.08, 103.20-111.11) 108.80 50.27 (104.10, 100.08-108.29) 48.29
AUC0-inf, μg.mL-1.hr 120.92 114.09 54.49 51.85
LS geometric means (ratio test/reference 
[%], 90% CI)
118.82 (106.99, 103.26-110.85) 111.06 52.95 (104.6, 100.56-108.82) 50.62
AUC0-t: area under the curve calculated by linear trapezoidal rule to the last measurable plasma concentration; AUC0-inf: area under the curve 
calculated by linear trapezoidal rule to the last measurable plasma concentration (Cp) with additional area calculated from Cp/Kel (elimination 
rate constant); Cmax: maximum plasma concentration; hr(s): hour(s); LS: least square; tmax: the time to occurrence of the maximum plasma 
concentration; t1/2: plasma concentration half life. aMedian values.Tanner et al. BMC Clinical Pharmacology 2010, 10:10
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Figure 1 Mean plasma ibuprofen concentration time curves after administration of ibuprofen monotherapy and ibuprofen-paracetamol 
fixed-dose combination tablets (Study 1).
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Figure 2 Mean plasma paracetamol concentration time curves after administration of paracetamol monotherapy and ibuprofen-paraceta-
mol fixed-dose combination tablets (Study 1).
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On Day 4, the plasma concentrations of both ibuprofen
and paracetamol pre-dose and 24 hours post-dose were
higher for subjects receiving three times daily dosing
compared with those receiving twice daily dosing (Figure
4). Overall, however, the mean plasma levels achieved for
both ibuprofen and paracetamol were similar for the two
different dosing regimes. Day 4 Cmax and tmax values for
ibuprofen and paracetamol were also similar for the dif-
ferent dosing groups. Both ibuprofen and paracetamol
Cmin and Cav values were, however, greater with three
times daily dosing; therefore, less fluctuation and swing
was observed compared with twice daily dosing. In addi-
tion, AUC0-t values for both ibuprofen and paracetamol
were higher following three times daily dosing but values
for AUCtau were similar between the dosing regimes.
Analysis of ratios of trough values on Days 2, 3 and 4
found that a steady state was reached for both ibuprofen
and paracetamol and no accumulation of either ibuprofen
or paracetamol was evident on Day 4. Variation in mean
trough concentrations was observed across the study
days; mean trough values for paracetamol were lower on
the first day of dosing compared with later study days,
and trough values observed for ibuprofen and paraceta-
mol were higher in the morning compared with those
Table 2: Mean derived pharmacokinetic profiles for ibuprofen and paracetamol after administration of the fixed-dose 
combination tables in the fed and fasted states (Study 1)
Ibuprofen Paracetamol
Fed Fasted Fed Fasted
n 25 25 25 25
tmax, hrs 2.00a 1.25a 1.50a 0.50a
Median difference [minutes] fed vs fasted, 95% CI 25.0, 0.0-45.0 55.0, 30.0-80.0
t1/2, hrs 2.25 1.95 2.73 2.83
Cmax, μg.mL-1 24.74 32.04 11.14 18.48
LS geometric mean 24.03 31.46 10.71 17.58
Ratio fed/fasted (%), 90% CI 76.38, 70.25-83.06 60.92, 53.43-69.46
AUC0-t, μg.mL-1.hr 103.91 118.32 46.45 51.69
LS geometric mean 101.6 2 116.51 45.69 50.27
Ratio fed/fasted (%), 90% CI 87.22, 84.06-90.49 90.89, 87.38-94.54
AUC0-inf, μg.mL-1.hr 109.03 120.92 49.51 54.49
LS geometric mean 106.04 118.82 48.72 52.95
Ratio fed/fasted (%), 90% CI 89.25, 86.14-92.46 92.01, 88.45-95.71
Kel 0.328 0.361 0.258 0.251
AUC0-inf: area under the curve calculated by linear trapezoidal rule to the last measurable plasma concentration (Cp) with additional area 
calculated from Cp/Kel; AUC0-t: area under the curve calculated by linear trapexoidal rule to the last measurable plasma concentration; Cmax: 
maximum plasma concentration; Kel: elimination rate constant; tmax: time of maximum plasma concentration; hr(s): hour(s); LS: least square; 
sd: standard deviation. aMedian values.Tanner et al. BMC Clinical Pharmacology 2010, 10:10
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seen in the afternoon and evening. Thus some statistical
differences in the comparison of trough values were
observed; LS geometric mean ratio for zero hours, Day 4,
versus 12 hours, Day 3, following ibuprofen twice daily
dosing, was 1.78 (95% CI 1.47-2.16; p < 0.0001, Figure 5);
LS geometric mean ratio for zero hours, Day 4, versus 16
hours, Day 3, for ibuprofen following three times daily
dosing was 1.38 (95% CI 1.19-1.61; p < 0.0001, Figure 6).
Comparison of trough levels obtained at the same time of
day did not show any significant differences between dos-
ing regimes.
Safety results
No significant changes in haematological or biochemical
values were observed during the course of either study
and no clinically significant safety issues were identified.
There were no serious AEs and all non-serious events
were categorised as mild or moderate. In Study 2 there
were four AEs recorded in three subjects that were con-
sidered possibly or probably related to study medication:
a rash on the left arm and trunk lasting between 11 and
21 hours; heartburn, resolving after 1.1 days; and cold like
symptoms, resolving after 12.7 hours.
Figure 3 Mean plasma ibuprofen and paracetamol concentration time curves after administration of ibuprofen-paracetamol fixed-dose 
combination tablets in the fed and fasted states (Study 1).
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Table 3: Mean derived comparison of the single-dose pharmacokinetic parameters in subjects allocated to the twice or 
three times daily dosing regimen (Study 2; Day 2)
Ibuprofen Paracetamol
Twice daily Three times daily Twice daily Three times daily
n 26 26 26 26
tmax, hrs 1.75a 1.25a 0.67a 0.67a
Cmax, μg.mL-1 (sd) 32.53 (6.15) 36.66 (8.14) 14.74 (5.76) 15.86 (4.76)
AUC0-t, μg.mL-1.hr (sd) 128.29 (23.60) 124.01 (23.35) 46.98 (12.42) 47.58 (12.79)
AUC0-inf, μg.mL-1.hr (sd) 130.67 (24.61) 132.27 (25.54) 49.23 (12.99) 52.49 (14.06)
AUC0-inf: area under the curve calculated by linear trapezoidal rule to the last measurable plasma concentration (Cp) with additional area 
calculated from Cp/Kel (elimination rate constant); AUC0-t: area under the curve calculated by linear trapexoidal rule to the last measurable 
plasma concentration; Cmax: maximum plasma concentration; hr(s): hour(s); tmax: time of maximum plasma concentration; t1/2: plasma 
concentration half life; sd: standard deviation. aMedian values.Tanner et al. BMC Clinical Pharmacology 2010, 10:10
http://www.biomedcentral.com/1472-6904/10/10
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Discussion
Ibuprofen and paracetamol are rapidly released from this
novel fixed-dose combination tablet containing 200 mg of
ibuprofen and 500 mg of paracetamol. The results
observed in Study 1 show that concurrent administration
of ibuprofen and paracetamol in this novel fixed-dose
combination tablet did not significantly alter the rate and
extent of absorption of ibuprofen or the extent of parac-
etamol absorption compared with either agent adminis-
tered alone. The rate of paracetamol absorption was,
however, significantly enhanced with the combination
tablet compared with paracetamol monotherapy. A previ-
ously published repeat-dose study on the pharmacoki-
netic profiles of ibuprofen (400 mg) and paracetamol (650
mg) showed a shorter, but not significant, tmax for parac-
etamol co-administered with ibuprofen (48 minutes)
compared with paracetamol monotherapy (54 minutes)
[6]. The 10 minute median decrease in tmax observed in
this study may be due either to the comparatively larger
dose of paracetamol used or to formulation characteris-
tics and the fact that the fixed-dose combination tablet is
very efficient at dissolution.
When the fixed-dose combination tablet was given in
the fed state, the rate of absorption of both ibuprofen and
paracetamol was delayed and this effect was particularly
pronounced for paracetamol; although, the Cmax value for
paracetamol remained within the range of therapeutic
plasma values considered effective [13]. This observed
delay is consistent with previously published studies of
ibuprofen and paracetamol monotherapy [13,14] and is
expected as the absorption of both drugs takes place in
the small intestine, and paracetamol absorption is known
to be dependent on gastric emptying [15]. Despite this
s l i g h t  d e la y  i n  a bso rp t i o n  o f  bo t h  d ru g s,  t h e  e x t e n t  o f
absorption of ibuprofen and paracetamol was similar
when the combination tablet was given in the fed or
fasted state. Both ibuprofen and paracetamol 90% CIs for
AUC0-t and AUC0-inf ratios were within the bioequiva-
lence acceptance range of 80 to 125% and, therefore, not
considered clinically significant. However, these confi-
Table 4: Comparison of the mean-derived pharmacokinetic parameters for ibuprofen and paracetamol after 
administration of the fixed-dose combination tablets, twice or three times daily for 3 days (Study 2; Day 4)
Ibuprofen Paracetamol
Twice daily Three times daily Twice daily Three times daily
n 26 26 26 26
tmax, hrs 1.50a 1.50a 0.67a 0.67a
Cmax, μg.mL-1 (sd) 33.4 (6.12) 33.55 (7.32) 16.09 (5.14) 15.87 (5.26)
Cmin, μg,mL-1 (sd) 0.72 (0.42) 2.64 (1.24) 0.74 (0.25) 1.87 (0.79)
Cav, μg.mL-1 (sd) 9.61 (1.96) 13.69 (2.73) 4.07 (1.05) 5.86 (1.68)
Fluctuation (sd) 3.44 (0.65) 2.26 (0.50) 3.83 (1.02) 2.47 (0.83)
(Cmax-Cmin)/Cav
Swing (sd)
(Cmax-Cmin)/Cmin
62.47 (40.28) 14.90 (8.72) 22.81 (10.05) 8.73 (4.78)
AUC0-t,
μg.mL-1.hr (sd)
230.73 (47.00) 328.60 (65.71) 97.67 (25.13) 140.80 (40.30)
AUCtau,
μg.mL-1.hr (sd)
118.12 (24.23) 114.26 (22.77) 51.72 (12.89) 50.74 (13.29)
AUCtau: area under the plasma concentration-time curve for a dosing interval; AUC0-t: area under the curve calculated by linear trapezoidal 
rule to the last measurable plasma concentration; Cav: average plasma concentration; Cmax: maximum plasma concentration; Cmin: minimum 
plasma concentration; hr(s): hour(s); tmax: time of maximum plasma concentration; sd: standard deviation. aMedian values.Tanner et al. BMC Clinical Pharmacology 2010, 10:10
http://www.biomedcentral.com/1472-6904/10/10
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Figure 4 Mean plasma ibuprofen and paracetamol concentrations time curves following administration of the first dose in subjects allo-
cated to receive twice or three times daily dosing with ibuprofen-paracetamol fixed-dose combination tablets (Study 2; Day 2).
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Figure 5 Comparison of mean plasma ibuprofen and paracetamol concentration time curves after administration of the first dose (on Day 
2) and following three days of treatment (Day 4) with ibuprofen-paracetamol fixed-dose combination tablets at twice daily dosing.
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dence intervals did not exceed 100% indicating that there
may be a non-significant reduction in the extent of
absorption.
In Study 2, the multi-dose pharmacokinetics of ibupro-
fen and paracetamol in the fixed-dose combination tablet
were observed to be comparable to the single-dose phar-
macokinetics. For ibuprofen, however, there was a slight
variation in the rate of absorption, indicating some intra-
subject variability. Furthermore, plasma levels of ibupro-
fen and paracetamol achieved by twice and three times
daily dosing were similar, although, as expected, trough
concentrations of both drugs were slightly higher follow-
ing three times relative to twice daily dosing.
A clear relationship between plasma concentrations
and degree of measured pain relief has been observed for
ibuprofen [16] and for paracetamol [17-19], although this
relationship is not as clear for paracetamol as for ibupro-
fen, as a lag between plasma concentration and therapeu-
tic affect is observed [20]. Based on these reported levels,
the novel combination tablet achieves therapeutic dose
levels of ibuprofen and paracetamol for approximately 12
hours per day and 8 hours per day when given three times
or twice daily, respectively. Therefore, the three times
daily dosing, with less fluctuation and swing in plasma
levels, offers greater exposure to clinically effective levels
of both ibuprofen and paracetamol, which may be associ-
ated with greater therapeutic benefit.
Ibuprofen and paracetamol are analgesic compounds
commonly used for treating mild to moderate pain. For
the relief of more severe pain, combination analgesia is
often recommended, as the combination of analgesics
with different modes of action has the potential to offer
enhanced pain relief with a comparatively lower dose of
each analgesic and corresponding reduced side effects
[21]. In both studies this novel ibuprofen and paraceta-
mol fixed-dose combination tablet was well tolerated.
The incidence of AEs was low, none of which were con-
sidered definitely associated with study medication.
Conclusion
The combination of ibuprofen and paracetamol in a
fixed-dose tablet does not significantly alter the pharma-
cokinetic profiles of either drug alone, although the rate
of paracetamol absorption is enhanced, offering potential
therapeutic benefits in relation to the onset of analgesia.
Concentrations of both ibuprofen and paracetamol reach
levels required for therapeutic effect when the fixed com-
bination formulation is administrated either in the fed or
fasted state. The multi-dose pharmacokinetics of the
fixed-dose combination tablet are comparable to the sin-
gle-dose pharmacokinetics and three times daily dosing
may offer enhanced therapeutic effect for longer than
twice daily dosing.
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Figure 6 Comparison of mean plasma ibuprofen and paracetamol concentration time curves after administration of the first dose (on Day 
2) and following three days of treatment (Day 4) with ibuprofen-paracetamol fixed-dose combination tablets at three times days daily dos-
ing.
Time (hours)
M
e
a
n
 
P
l
a
s
m
a
 
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
μ
g
.
m
L
−
1
)
Ibuprofen - Day 4 three times daily
Ibuprofen - Day 2 first dose 
Paracetamol - Day 4 three times daily
Paracetamol - Day 2 first dose 
0  1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18 19 20 21 22  23 24
30
25
20
35
15
10
0
5Tanner et al. BMC Clinical Pharmacology 2010, 10:10
http://www.biomedcentral.com/1472-6904/10/10
Page 12 of 12
Authors' contributions
TTa helped design the studies, derived the pharmacokinetic parameters and
reviewed the statistical analysis. TTh and AM were involved in the technical
undertaking of this study; TTh was responsible for paracetamol bioanalysis and
AM for ibuprofen bioanalysis. SA participated in the design of the studies,
wrote the protocols and managed the conduct and reporting of the study on
behalf of the sponsor. All authors contributed to the content and review of the
manuscript and read and approved the final manuscript.
Authors' information
Trevor Tanner is Scientific Director at Simbec Research (Merthyr Tydfil, Wales,
UK). Tracy Thomas and Andrew Munn are Principal Scientists in the Bioanalyti-
cal Unit at Simbec Research. Sue Aspley is an employee of Reckitt Benckiser
Healthcare International Ltd.
Acknowledgements
This study was sponsored by Reckitt Benckiser Healthcare International Ltd and 
editorial assistance was provided by Debra Scates of Elements Communica-
tions Ltd, supported by Reckitt Benckiser Healthcare International Ltd. Trevor 
Tanner, Tracy Thomas and Andrew Munn are employees of Simbec Research 
(Merthyr Tydfil, Wales, UK) and Sue Aspley is an employee of Reckitt Benckiser 
Healthcare International Ltd.
Author Details
1Simbec Research Ltd, Cardiff Road, Merthyr Tydfil, CF48 4DR, UK and 2Reckitt 
Benckiser Healthcare UK Ltd, Dansom Lane, Hull, Yorkshire, HU8 7DS, UK
References
1. Vane JR, Botting RM: Mechanism of action of anti-inflammatory drugs.  
Scand J Rheumatol Suppl 1996, 102:9-21.
2. Bonnefont J, Courade JP, Alloui A, Eschalier A: Antinociceptive 
mechanism of action of paracetamol.  Drugs 2003, 63(Spec No 2):1-4.
3. Dollery C: Therapeutic Drugs.  Volume 2. Churchill Livingstone; 1999. 
4. Schachtel BP, Fillingim JM, Thoden WR, Lane AC, Baybutt RI: Sore throat 
pain in the evaluation of mild analgesics.  Clin Pharmacol Ther 1988, 
44:704-711.
5. Sunshine A, Olson NZ, Laska EM, Zighelboim I, De Castro A, De Sarrazin C: 
Ibuprofen, zomepirac, aspirin, and placebo in the relief of 
postepisiotomy pain.  Clin Pharmacol Ther 1983, 34:254-258.
6. Wright CE III, Antal EJ, Gillespie WR, Albert KS: Ibuprofen and 
acetaminophen kinetics when taken concurrently.  Clin Pharmacol Ther 
1983, 34:707-710.
7. CPMP/EWP/QWP/1401/98: Note for Guidance on the Investigation of 
Bioavailability and Bioequivalence 2001 [http://www.emea.europa.eu/
pdfs/human/qwp/140198enrev1.pdf].
8. CPMP/EWP/240/95: Note for Guidance on Fixed Combination Medicinial 
Products 1996 [http://www.ikev.org/haber/bioav/024095en.pdf].
9. US department of Health and Human Services FaDCfDEaRC: Guidance for 
Industry: Bioavailability and Bioequivalence for Orally Administered Drug 
Products - General Consideration 2001 [http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
ucm070124.pdf].
10. US department of Health and Human Services FaDCfDEaRC: Guidance for 
Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies 2002 
[http://www.fda.gov/downloads/RegulatoryInformation/Guidances/
UCM126833.pdf].
11. Diletti E, Hauschke D, Steinijans VW: Sample size determination for 
bioequivalence assessment by means of confidence intervals.  Int J Clin 
Pharmacol Ther Toxicol 1991, 29:1-8.
12. Chen X, Huang J, Kong Z, Zhong D: Sensitive liquid chromatography-
tandem mass spectrometry method for the simultaneous 
determination of paracetamol and guaifenesin in human plasma.  
Journal of Chromatography B 2005, 817:263-269.
13. Prescott LF: Paracetamol (acetaminophen). A Critical Bibliographic 
Review.  Taylor and Francis Publishers; 2000:289-297. 
14. Davies NM: Clinical pharmacokinetics of ibuprofen The first 30 years.  
Clin Pharmacokinet 1998, 34:101-154.
15. Forrest JA, Clements JA, Prescott LF: Clinical pharmacokinetics of 
paracetamol.  Clin Pharmacokinet 1982, 7:93-107.
16. Laska EM, Sunshine A, Marrero I, Olson N, Siegel C, McCormick N: The 
correlation between blood levels of ibuprofen and clinical analgesic 
response.  Clin Pharmacol Ther 1986, 40:1-7.
17. Anderson BJ, Holford NH, Woollard GA, Kanagasundaram S, Mahadevan 
M: Perioperative pharmacodynamics of acetaminophen analgesia in 
children.  Anesthesiology 1999, 90:411-421.
18. Brown RD, Kearns GL, Wilson JT: Integrated pharmacokinetic-
pharmacodynamic model for acetaminophen, ibuprofen, and placebo 
antipyresis in children.  J Pharmacokinet Biopharm 1998, 26:559-579.
19. Rumack BH: Aspirin versus acetaminophen: a comparative view.  
Pediatrics 1978, 62:943-946.
20. Seymour RA, Rawlins MD: Pharmacokinetics of parenteral paracetamol 
and its analgesic effects in post-operative dental pain.  Eur J Clin 
Pharmacol 1981, 20:215-218.
21. Raffa RB: Pharmacology of oral combination analgesics: rational 
therapy for pain.  Journal of Clinical Pharmacology 2001, 26:257-64.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6904/10/10/prepub
doi: 10.1186/1472-6904-10-10
Cite this article as: Tanner et al., The pharmacokinetic profile of a novel 
fixed-dose combination tablet of ibuprofen and paracetamol BMC Clinical 
Pharmacology 2010, 10:10
Received: 23 November 2009 Accepted: 5 July 2010 
Published: 5 July 2010
This article is available from: http://www.biomedcentral.com/1472-6904/10/10 © 2010 Tanner et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Clinical Pharmacology 2010, 10:10